Strategies to Screen Anti-AQP4 Antibodies from Yeast Surface Display Libraries
Name
antibodies-11-00039-v2.pdf
Description
Published version
Size
3.18 MB
Format
Adobe PDF
Checksum (MD5)
5451e5586d7135786c9717d4e023c54e
Author(s) • • • • • • • • •
Huang, Aric
Jin, Wei
Fahad, Ahmed S
Mussman, Brooklyn K
Nicchia, Grazia Paola
Madan, Bharat
de Souza, Matheus Oliveira
Griffin, J Daniel
Bennett, Jeffrey L
Frigeri, Antonio
Date Issued
2022
Journal
Antibodies
Publisher
MDPI AG
Citation
Huang, Aric, Jin, Wei, Fahad, Ahmed S, Mussman, Brooklyn K, Nicchia, Grazia Paola et al. 2022. "Strategies to Screen Anti-AQP4 Antibodies from Yeast Surface Display Libraries." Antibodies, 11 (2).
Version
Final published version
Abstract
A rapid and effective method to identify disease-specific antibodies from clinical patients is important for understanding autoimmune diseases and for the development of effective disease therapies. In neuromyelitis optica (NMO), the identification of antibodies targeting the aquaporin-4 (AQP4) membrane protein traditionally involves the labor-intensive and time-consuming process of single B-cell sorting, followed by antibody cloning, expression, purification, and analysis for anti-AQP4 activity. To accelerate patient-specific antibody discovery, we compared two unique approaches for screening anti-AQP4 antibodies from yeast antibody surface display libraries. Our first approach, cell-based biopanning, has strong advantages for its cell-based display of native membrane-bound AQP4 antigens and is inexpensive and simple to perform. Our second approach, FACS screening using solubilized AQP4 antigens, permits real-time population analysis and precision sorting for specific antibody binding parameters. We found that both cell-based biopanning and FACS screening were effective for the enrichment of AQP4-binding clones. These screening techniques will enable library-scale functional interrogation of large natively paired antibody libraries for comprehensive analysis of anti-AQP4 antibodies in clinical samples and for robust therapeutic discovery campaigns.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.3390/ANTIB11020039